This was accomplished by increasing hepatic SIRT1 protein activity, deacetylating SIRT1 targets, decreasing caspase-1 activation, and reducing hepatic inflammation, indicating APO10LA as having anti-inflammatory and anti-tumor effects in MASLD-HCC models (Ip et al., 2013). This evidence concerns the gene SIRT1 and neoplasm.